Didanosine

Didanosine
Clinical data
Trade namesVidex, Videx EC
Other names2′,3′-dideoxyinosine, DDI
AHFS/Drugs.comMonograph
MedlinePlusa691006
Pregnancy
category
  • AU: B2
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability30 to 54%
Protein bindingLess than 5%
Elimination half-life1.5 hours
ExcretionKidney
Identifiers
  • 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.129.182 Edit this at Wikidata
Chemical and physical data
FormulaC10H12N4O3
Molar mass236.231 g·mol−1
3D model (JSmol)
  • O=C3/N=C\Nc1c3ncn1[C@@H]2O[C@@H](CC2)CO
  • InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 checkY
  • Key:BXZVVICBKDXVGW-NKWVEPMBSA-N checkY
  (verify)

Didanosine, sold under the brand name Videx among others, is a medication used to treat HIV/AIDS.[2] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class.

Didanosine was first described in 1975 and approved for use in the United States in 1991.[3]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ "didanosine, Videx, Videx EC: Drug Facts, Side Effects and Dosing". MedicineNet. Retrieved 8 August 2018.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 505. ISBN 9783527607495.